Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 299, Issue 4, 2010, Pages

  Halbirk, Mads ^a   Nørrelund, Helene ^b   Møller, Niels ^a   Schmitz, Ole ^a   Gøtzsche, Liv ^a   Nielsen, Roni ^a   Nielsen Kudsk, Jens Erik ^a   Nielsen, Søren Steen ^a   Nielsen, Torsten Toftegaard ^a   Eiskjær, Hans ^a   Bøtker, Hans Erik ^a   Wiggers, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

Author keywords

Insulin resistance; Metabolism

Indexed keywords

ACIPIMOX; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FATTY ACID; GLUCOSE; INSULIN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; EXERCISE; FEMALE; HEART FAILURE; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERINSULINEMIA; ISCHEMIC HEART DISEASE; MALE; METABOLIC PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC VASCULAR RESISTANCE; TISSUE DOPPLER IMAGING;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FATTY ACIDS, NONESTERIFIED; FEMALE; HEART; HEART FAILURE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; METABOLISM; MIDDLE AGED; PYRAZINES; STROKE VOLUME; VASCULAR RESISTANCE;

EID: 77958051227     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00475.2010     Document Type: Article

References (34)

1. Agostoni P, Cattadori G, Apostolo A, Contini M, Palermo P, Marenzi G, Wasserman K. Noninvasive measurement of cardiac output during exercise by inert gas rebreathing technique: a new tool for heart failure evaluation. J Am Coll Cardiol 46: 1779-1781, 2005. (Pubitemid 41531639)
2. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349: 1050-1053, 1997. (Pubitemid 27158249)
3. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes 47: 1643-1649, 1998. (Pubitemid 28445355)
4. 18F]fluorodeoxyglucose. J Nucl Cardiol 4: 125-132, 1997.
5. Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 172: 641-645, 1962.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.
7. Corbett JM, Why HJ, Wheeler CH, Richardson PJ, Archard LC, Yacoub MH, Dunn MJ. Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 19: 2031-2042, 1998.
8. Davila-Roman VG, Vedala G, Herrero P, de las FL, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40: 271-277, 2002.
9. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, Camici PG. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol 48: 2225-2231, 2006. (Pubitemid 44855434)
10. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27: 942-948, 2006.
11. Lassers BW, Wahlqvist ML, Kaijser L, CARLSONLA. Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise. J Appl Physiol 33: 72-80, 1972.
12. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, Ashrafian H, Horowitz J, Fraser AG, Clarke K, Frenneaux M. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112: 3280-3288, 2005. (Pubitemid 43739373)
13. Lei B, Lionetti V, Young ME, Chandler MP, d' Agostino C, Kang E, Altarejos M, Matsuo K, Hintze TH, Stanley WC, Recchia FA. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36: 567-576, 2004.
14. Maki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki LM, Ruotsalainen U, Haaparanta M, Solin O, Hartiala J, Harkonen R, Knuuti J. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 93: 1658-1666, 1996. (Pubitemid 26131342)
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985. (Pubitemid 15018832)
16. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 364: 1786-1788, 2004.
17. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151, 2007. (Pubitemid 46425598)
18. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408, 2005. (Pubitemid 41698549)
19. Norrelund H, Wiggers H, Halbirk M, Frystyk J, Flyvbjerg A, Botker HE, Schmitz O, Jorgensen JO, Christiansen JS, Moller N. Abnormalities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 260: 11-21, 2006. (Pubitemid 43894065)
20. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, Bergman J, Solin O, Voipio-Pulkki LM, Wegelius U. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 89: 1767-1774, 1992.
21. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 54: 1637-1646, 2009.
22. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106: 606-612, 2002. (Pubitemid 34827712)
23. Pleissner KP, Regitz-Zagrosek V, Weise C, Neuss M, Krudewagen B, Soding P, Buchner K, Hucho F, Hildebrandt A, Fleck E. Chamber-specific expression of human myocardial proteins detected by two-dimensional gel electrophoresis. Electrophoresis 16: 841-850, 1995.
24. Randle PJ, Newsholme EA, Garland PB. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J 93: 652-655, 1964.
25. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699, 2006. (Pubitemid 44881367)
26. Sondergaard HM, Bottcher M, Marie MM, Schmitz O, Hansen SB, Nielsen TT, Botker HE. Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease. J Clin Endocrinol Metab 91: 4854-4861, 2006. (Pubitemid 44917318)
27. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005. (Pubitemid 40894649)
28. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, Stevenson JC, Coats AJ. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30: 527-532, 1997. (Pubitemid 27339335)
29. Tuunanen H, Engblom E, Naum A, Scheinin M, Nagren K, Airaksinen J, Nuutila P, Iozzo P, Ukkonen H, Knuuti J. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 12: 644-652, 2006. (Pubitemid 44512144)
30. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KEJ, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 114: 2130-2137, 2006. (Pubitemid 44747893)
31. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B, Airaksinen KEJ, Nuutila P, Iozzo P, Ukkonen H, Opie LH, Knuuti J. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 118: 1250-1258, 2008.
32. van Bilsen M, van Nieuwenhoven FA, van der Vusse GJ. Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res 81: 420-428, 2009.
33. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ, Stone CK. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 103: 2441-2446, 2001. (Pubitemid 32493369)
34. Wiggers H, Norrelund H, Nielsen SS, Andersen NH, Nielsen-Kudsk JE, Christiansen JS, Nielsen TT, Moller N, Botker HE. Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. Am J Physiol Heart Circ Physiol 289: H938-H946, 2005. (Pubitemid 41129413)